{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T12:08:10Z","timestamp":1756382890569,"version":"3.44.0"},"reference-count":20,"publisher":"BMJ","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DTB"],"published-print":{"date-parts":[[2011,10]]},"abstract":"<jats:p>\u25bcDabigatran etexilate (Pradaxa \u2013 Boehringer Ingelheim) is an oral anticoagulant that has been licensed in the EU since 2008 for thromboprophylaxis in adults following a hip or knee joint replacement.1 The marketing authorisation for the drug in the EU has recently been extended to include the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF). In theory, dabigatran could offer an advantage to patients who need anticoagulation because, unlike warfarin, its dose does not need to be individually adjusted and its effects do not require regular monitoring through blood sampling. Here we review the evidence for dabigatran in this new indication and consider its place in the management of patients with AF.<\/jats:p>","DOI":"10.1136\/dtb.2011.02.0060","type":"journal-article","created":{"date-parts":[[2011,10,12]],"date-time":"2011-10-12T06:46:45Z","timestamp":1318402005000},"page":"114-117","source":"Crossref","is-referenced-by-count":5,"title":["Should \u25bcdabigatran replace warfarin for stroke prevention in AF?: Table"],"prefix":"10.1136","volume":"49","member":"239","published-online":{"date-parts":[[2011,10,12]]},"reference":[{"key":"2025082623214965000_49.10.114.1","doi-asserted-by":"publisher","DOI":"10.1136\/dtb.2009.09.0041"},{"key":"2025082623214965000_49.10.114.2","unstructured":"The Information Centre, 2010. Prevalence. Quality and Outcomes Framework (QOF) for April 2009 \u2013 March 2010, England [online]. Available: http:\/\/www.ic.nhs.uk\/webfiles\/QOF\/2009-10\/Prevalence%20tables\/QOF0910_National_Prevalence_Aug_2011.xls [Accessed 22 September 2011]."},{"key":"2025082623214965000_49.10.114.3","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehq278"},{"key":"2025082623214965000_49.10.114.4","doi-asserted-by":"crossref","unstructured":"Keeling D . Guidelines on oral anticoagulation with warfarin - fourth edition. Br J Haematol 2011; doi:10.1111\/j.1365-2141.2011.08753.x.","DOI":"10.1111\/j.1365-2141.2011.08753.x"},{"key":"2025082623214965000_49.10.114.5","unstructured":"National Collaborating Centre for Chronic Conditions, 2006. Atrial fibrillation. National clinical guideline for management in primary and secondary care [online]. Available: http:\/\/www.nice.org.uk\/nicemedia\/live\/10982\/30055\/30055.pdf. [Accessed 22 September 2011]."},{"key":"2025082623214965000_49.10.114.6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d124"},{"key":"2025082623214965000_49.10.114.7","doi-asserted-by":"crossref","unstructured":"Pisters R . A novel user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; doi 10.1378\/chest.10-0134.","DOI":"10.1378\/chest.10-0134"},{"key":"2025082623214965000_49.10.114.8","doi-asserted-by":"publisher","DOI":"10.1136\/dtb.2009.08.0036"},{"key":"2025082623214965000_49.10.114.9","unstructured":"Pradaxa 150mg hard capsules. Summary of product characteristics, EU. Boehringer Ingelheim International GmbH, August 2011."},{"key":"2025082623214965000_49.10.114.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905561"},{"key":"2025082623214965000_49.10.114.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1007378"},{"key":"2025082623214965000_49.10.114.12","doi-asserted-by":"crossref","unstructured":"Wallentin L . Efficacy and safety of dabigatran compared with warfarin at different levels ofinternational normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010; doi: 10.10.1016\/S0140-6736(10)61194-4.","DOI":"10.1016\/S0140-6736(10)61194-4"},{"key":"2025082623214965000_49.10.114.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe0906886"},{"key":"2025082623214965000_49.10.114.14","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2011.308"},{"key":"2025082623214965000_49.10.114.15","first-page":"295","article-title":"P-glycoprotein: why is it significant","volume":"286","author":"Sawyer","year":"2011","journal-title":"Pharm J"},{"key":"2025082623214965000_49.10.114.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1103050"},{"key":"2025082623214965000_49.10.114.17","doi-asserted-by":"crossref","unstructured":"Pugh D . Attitudes of physicians regarding anticoagulation for atrial fibrillation: a systematic review. Age Ageing 2011; doi:10.1093\/ageing\/afr097.","DOI":"10.1093\/ageing\/afr097"},{"key":"2025082623214965000_49.10.114.18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2008.03059.x"},{"key":"2025082623214965000_49.10.114.19","unstructured":"West Yorkshire Cardiac Network, 2011 Economic appraisal of dabigatran etexilate 150mg compared warfarin or aspirin in patients with atrial fibrillation. Updated report [online]. Available: http:\/\/www.yorksandhumberhearts.nhs.uk\/upload\/WYCN\/Dabigatran\/YHEC%20Dabigatran%20Feb%202011.pdf [Accessed 22 September 2011]."},{"key":"2025082623214965000_49.10.114.20","unstructured":"Scottish Medicines Consortium, 2011. Dabigatran etexilate 110mg and 150mg hard capsules (Pradaxa) SMC No. (672\/11) [online]. Available: http:\/\/www.scottishmedicines.org.uk\/files\/advice\/dabigatran_Pradaxa_FINAL_August_2011_Amended_05.09.11_for_website.pdf [Accessed 22 September 2011]."}],"container-title":["Drug and Therapeutics Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/dtb.2011.02.0060","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T06:22:01Z","timestamp":1756275721000},"score":1,"resource":{"primary":{"URL":"https:\/\/dtb.bmj.com\/lookup\/doi\/10.1136\/dtb.2011.02.0060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":20,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2011,10,12]]},"published-print":{"date-parts":[[2011,10]]}},"alternative-id":["10.1136\/dtb.2011.02.0060"],"URL":"https:\/\/doi.org\/10.1136\/dtb.2011.02.0060","relation":{},"ISSN":["0012-6543","1755-5248"],"issn-type":[{"type":"print","value":"0012-6543"},{"type":"electronic","value":"1755-5248"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}